Leo Pharma wants to be first in US with hand eczema treatment

After securing fast-track status from the FDA, Leo Pharma hopes to become the first company in the US to specifically address chronic hand eczema, for which there is no treatment in the country.

Photo: Leo Pharma / PR

In many ways, Leo Pharma is headed into unknown territory after the firm secured fast-track status for its drug candidate delgocitinib from the US Food and Drug Administration, FDA.

The company could become the first to send a drug to market in the US specifically targeting chronic hand eczema, for which delgocitinib has received a special status.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Latest news

See all jobs